Focus on Biosimilars
Biosimilars represent one of the pillars of Actavis’ strategy to drive long-term growth. We are committed to building a leadership position in this emerging global market.
Actavis Pharma’s North American Specialty Brand business’ biosimilar product pipeline currently consists of five products in various stages of development: one product for the treatment of female infertility being developed internally and four oncology products being developed in collaboration with Amgen.
This strategy, which is supported by our biosimilars team, formally known as Eden Biodesign, was expanded in December 2011 with the announcement of our collaboration with Amgen to develop and commercialize, on a worldwide basis, biosimilar versions of Herceptin®, Avastin®, Rituxan/Mab Thera®, and Erbitux®.
These products represent some of the fastest-growing pharmaceutical products in the world with peak innovator sales topping $20 billion.
In July 2012, Actavis entered into a global license agreement with Synthon, obtaining an exclusive license to its biosimilar version of Herceptin®, an FDA approved treatment for breast and gastric cancers. Actavis subsequently contributed the product to the Amgen/Actavis collaboration.
This collaboration places Amgen and Actavis in an unparalleled position in the global biosimilars market by capitalizing on best-in-class capabilities in both innovative biologics and specialty pharmaceuticals and generics.
It delivers on Actavis’ promise to be a leader in the field of biosimilars, and does so in a way that helps manage the substantial financial investment, operational capabilities and broad commercial skills required to bring safe, high-quality and cost-effective biosimilar therapies to patients.
The Amgen/Actavis collaboration is in addition to Actavis’ ongoing efforts to develop and commercialize Itero Biopharmaceuticals, Inc.’s recombinant follicle stimulating hormone (rFSH) product as a biosimilar molecule for the treatment of female infertility.